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Biomarker exploration in Human 
peripheral Blood Mononuclear 
cells for Monitoring Sulforaphane 
treatment Responses in Autism 
Spectrum Disorder
Hua Liu1,2*, Andrew W. Zimmerman3,4, Kanwaljit Singh3, Susan L. connors3, Eileen Diggins3, 
Katherine K. Stephenson1,2, Albena T. Dinkova-Kostova1,2,5 & Jed W. fahey1,2,6,7
Autism Spectrum Disorder (ASD) is one of the most common neurodevelopmental disorders with no 
drugs treating the core symptoms and no validated biomarkers for clinical use. The multi-functional 
phytochemical sulforaphane affects many of the biochemical abnormalities associated with ASD. We 
investigated potential molecular markers from three ASD-associated physiological pathways that can 
be affected by sulforaphane: redox metabolism/oxidative stress; heat shock response; and immune 
dysregulation/inflammation, in peripheral blood mononuclear cells (PBMCs) from healthy donors and 
patients with ASD. We first analyzed the mRNA levels of selected molecular markers in response to 
sulforaphane ex vivo treatment in PBMCs from healthy donors by real-time quantitative PCR. All of the 
tested markers showed quantifiability, accuracy and reproducibility. We then compared the expression 
levels of those markers in PBMCs taken from ASD patients in response to orally-delivered sulforaphane. 
The mRNA levels of cytoprotective enzymes (NQO1, HO-1, AKR1C1), and heat shock proteins (HSP27 
and HSP70), increased. Conversely, mRNA levels of pro-inflammatory markers (IL-6, IL-1β, COX-2 
and tnf-α) decreased. Individually none is sufficiently specific or sensitive, but when grouped by 
function as two panels, these biomarkers show promise for monitoring pharmacodynamic responses to 
sulforaphane in both healthy and autistic humans, and providing guidance for biomedical interventions.
Autism Spectrum Disorder (ASD) is one of the most common neurodevelopmental disorders that, in the United 
States, is currently estimated to affect 1 out of 59 children who are 8 years old1. Despite decades of research and 
advances in our knowledge of the etiologies of ASD, treatments and biomarkers for ASD remain limited2–5. To 
date, the primary diagnosis of ASD still relies on observational tools that are by nature subjective3,6. Genetic and 
metabolic studies may provide additional clues to specific etiologies or treatments, but there are no generally 
accepted biological markers for commonly affected cellular pathways in ASD5,6.
Studies over the last two decades have implicated that physiological and metabolic abnormalities, such as 
immune dysregulation/neuro-inflammation, redox imbalance/oxidative stress, mitochondrial dysfunction, envi-
ronmental toxicant exposures and gut dysbiosis, are important aspects of the pathophysiology of ASD6. Closer 
examination of the biological markers of pathways associated with ASD could be informative regarding its 
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pathophysiology, and might be useful for early identification, prognosis and treatment. Most importantly, they 
might guide treatment strategies and enable clinicians to monitor treatment responses3,7.
Since ASD is multi-factorial and multiple genes have been implicated with no specific drug targets, strategies 
using multi-functional phytochemicals are highly attractive. Sulforaphane [1-isothiocyanato-4-(methylsulfi-
nyl)-butane, SF] is a dietary phytochemical, derived from its biologically inactive precursor glucoraphanin (GR) 
that is widely consumed in the edible cruciferous plant, broccoli (Brassica oleracea var. italica). SF is produced by 
the action of the enzyme myrosinase, which is present in cruciferous plant cells and is normally segregated from 
GR until the cells are ruptured8,9. Myrosinase is also produced by the microflora of the gastrointestinal tract of 
all healthy humans10,11. For over two decades, evidence of the beneficial effects of SF has accumulated, extending 
from in vitro studies, to animal models, to a variety of clinical studies6,12–15. Importantly, there are currently no 
drugs approved to treat the core symptoms of ASD, nor are there any studies using SF in genetic mouse models 
of ASD16. The cytoprotective potential of SF extending even to maternal dietary supplementation to prevent 
perinatal brain injury has been considered17. In our previous placebo-controlled, double-blinded, randomized 
clinical trial, daily administration of SF for 4-18 weeks substantially improved the behavioral abnormalities of the 
majority of 26 young males with moderate to severe ASD without significant toxicity18,19.
SF is a multi-functional phytochemical that acts upon many of the same biochemical and molecular (bio-
marker) pathways in which abnormalities have been ascribed to ASD, including oxidative stress, mitochondrial 
dysfunction, and neuroinflammation6,20–27. SF is one of the most potent naturally occurring inducers of mam-
malian cytoprotective enzymes through the Kelch-like ECH associated protein 1 (Keap1)/Nuclear factor eryth-
roid 2-related factor 2 (Nrf2)/antioxidant response element (ARE) signaling pathway (Fig. 1). Nrf2 activation is 
increasingly understood to play a significant role in ameliorating many diseases, including neurological disor-
ders28. This is in part a consequence of the recognized role of oxidative stress and chronic inflammation as caus-
ative factors for these disorders, and Nrf2 is the master regulator of cellular redox homeostasis and an inhibitor 
of inflammation, both of which are critical factors in the neuropathology of ASD29,30. The brain is particularly 
vulnerable to oxidative stress because of its high oxygen consumption, high content of unsaturated fatty acids and 
transition metals, and low antioxidant defense capacities31,32. SF has also shown strong anti-inflammatory activity 
in various settings, including animal models of neuroinflammation25,33,34. The anti-inflammatory activity of SF 
is partially Nrf2-dependent35 and is additionally mediated through inhibition of the nuclear factor-κB (NF-κB) 
pathway (Fig. 1), resulting in decreased expression of many cytokines and other pro-inflammatory factors36,37. 
Nrf2 itself also exhibits robust anti-inflammatory activity through at least three independent and critical mech-
anisms: modulation of redox metabolism; crosstalk with NF-κB; and direct negative regulation of proinflamma-
tory genes6,26,32,35,38–40.
Although the widespread anecdotal reports of the fever response in a substantial fraction of autistic patients 
have been corroborated41,42, the mechanisms of the “fever effect” in patients with ASD are just beginning to be 
understood43. Fever may activate general cellular stress responses, which involve at least two cellular signaling 
pathways: the Keap1/Nrf2/ARE cytoprotective pathway and the heat shock/proteasomal pathway that protects 
against a wide variety of disturbances of cellular functions, and these two pathways are interrelated44,45. SF has 
been shown to be an efficient inducer of a number of heat shock proteins (HSPs) in several human cell lines46–48, 
suggesting that activation of the heat shock response could be another contributing factor to SF-mediated pro-
tection in ASD.
In search for biomarkers for monitoring responses to SF treatment in ASD, we investigated several potential 
molecular markers from three ASD-associated basic physiological pathways that can be affected by SF (Fig. 1a–c): 
(1) redox metabolism/oxidative stress, (2) heat shock response, and (3) immune dysregulation/inflammation, 
in peripheral blood mononuclear cells (PBMCs). To optimize the methodology, we first isolated PBMCs from 
fresh human blood from healthy donors, and exposed these cells to SF ex vivo. We then examined a subset of 
Figure 1. Major signaling pathways for protective mechanisms against ASD by SF. (a) Keap1/Nrf2/ARE 
pathway, (b) NF-κB inflammatory pathway, (c) heat-shock responses. (modified from Liu et al.6).
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these markers in PBMCs from blood taken from subjects with ASD before and after 14 d of daily ingestion of 
a SF-providing nutritional supplement, calculated to deliver approximately the same daily dose of SF as was 
provided in our previous study18. Criteria evaluated for the biomarkers in these PBMCs included quantifiability, 
accuracy and reproducibility of the assay methods, as well as sensitivity and responsiveness to both ex vivo and 
in vivo SF treatments.
Results
Sulforaphane induced cytoprotective gene expression in human PBMCs with ex vivo treat-
ment. There is a long history of studies showing that ASD is associated with oxidative stress and diminished 
antioxidant capacity49–51. Eukaryotic organisms have developed highly efficient protective mechanisms, which do 
not normally operate at their maximal capacity, but can be induced to maintain cellular redox homeostasis and to 
reduce oxidative stress by production of direct antioxidants, and by induction of detoxifying enzymes, primarily 
through the Keap1/Nrf2/ARE pathway (Fig. 1)21,52,53. Much evidence also points to the neuroprotective role of 
HSPs, and the enhanced susceptibility of cells to damage when HSPs are suppressed54.
To evaluate the potential of using the expression levels of some of these cytoprotective genes as biomarkers 
for ASD treatment with SF, we first analyzed the mRNA levels of selected molecular markers of the Keap1/Nrf2/
ARE pathway and the heat shock pathway in response to SF ex vivo treatment in human PBMCs isolated from 
healthy donors. Expression of Keap1/Nrf2/ARE pathway-related markers, including Nrf2, Keap1, NAD(P)H: qui-
none oxidoreductase-1 (NQO1), heme oxygenase-1 (HO-1), and aldo-keto reductases (AKR1C1 and AKR1B10), 
were analyzed by quantitative real-time PCR. NQO1, HO-1 and AKR1C1 were significantly induced by 6-h 
SF treatment. This time point was chosen based on our earlier observations of the kinetics of upregulation of 
Nrf2-dependent genes by SF, and was expected to capture the increased mRNA production of both very fast (HO-
1) and relatively slow (NQO1) responders55. Interestingly, AKR1C1 was the most highly inducible Nrf2-target 
gene (up to a 5-fold increase), but the functionally-related AKR1B10 was not inducible. The mRNA levels for 
Keap1 increased slightly, and those for Nrf2 did not change significantly in response to SF treatment (Fig. 2a).
Expression of HSP70 and HSF1, two markers of heat shock response, were also analyzed in PBMCs by 
real-time PCR. HSP70 was slightly but significantly elevated by SF treatment, whereas HSF1 did not change 
(Fig. 2a).
Notably, there was no concentration-dependence in the induction of any of the genes examined, with the 
higher (5 μM) concentration of SF even showing a slightly diminished effect for the induction of AKR1C1 and 
NQO1. Although this concentration is achievable in vivo55, more typical peak concentrations of SF (and its 
metabolites) in human plasma are 1-2 μM56. In order to evaluate whether PBMCs would respond to repeated, 
lower dose SF ex vivo treatment, isolated PBMCs from healthy donors were exposed to vehicle (0.1% acetonitrile) 
or low concentration SF (0.5 μM) repeatedly, every 24 hours for 3 consecutive days, which we felt would be more 
relevant to the clinical condition, although SF metabolites in this scenario might not be identical to in vivo treat-
ment. Six hours after the last treatment, cells were collected and the expression of the same markers was analyzed. 
AKR1C1 was significantly induced by this multiple low dose SF treatment to similar extent as by a single higher 
dose SF treatment, while NQO1 was significantly, but less robustly induced by this lower concentration of SF 
(Fig. 2b). None of the other genes that we measured were significantly altered by repeated low dose SF treatments 
(Fig. 2b).
Sulforaphane decreased pro-inflammatory gene expression stimulated by LPS in human 
PBMCs with ex vivo treatment. Inflammation and immune dysregulation have been observed both 
within the brain and in the periphery in ASD patients6,51,57–63. Increased expression of immune-related genes, 
production of atypical pro-inflammatory cytokines and other inflammatory factors, all lead to a chronic state 
of inflammation in the central nervous system and in the peripheral immune system of ASD patients51,64,65. 
Expression of pro-inflammatory markers can be up-regulated by inflammatory mediators such as the bacterial 
endotoxin lipopolysaccharide (LPS), through the I kappa B kinase (IκK)/NF-κB pathway (Fig. 1). In addition, 
Figure 2. Cytoprotective gene expression in human PBMCs from healthy donors in response to SF ex vivo 
treatment. (a) Single dose. (b) Three consecutive, and lower daily doses. In each case assessment was made 
6 hours following the final dose. Means ± SD are shown. Symbols *(P < 0.05) or **(P < 0.01) indicate statistical 
differences between treatments and controls by two-tailed Student’s t-test.
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postnatal LPS challenge (at days 5 and 7 after birth) has been reported to cause depressive, anxiety-like, repet-
itive behavior, and working memory deficits in pre-adolescent (35-day-old) male mice66. We therefore treated 
PBMCs obtained from healthy donors with 1 ng/mL or 10 ng/mL of LPS for 5 hours, following which, expression 
of pro-inflammatory markers inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), tumor necrosis 
factor-α (TNF-α), interlukin-6 (IL-6) and interlukin-1β (IL-1β) were analyzed by real-time PCR. All inflamma-
tory markers except for iNOS were responsive to the LPS stimulation, especially IL-6 and IL-1β (up to several 
hundred-fold), and were more responsive to the lower dose of LPS (Fig. 3a). Thirty minutes pre-treatment by SF 
inhibited the LPS-stimulated up-regulation of COX-2, TNF-α, IL-6 and IL-1β expression up to 80% of control 
levels (Fig. 3b).
Biomarkers show consistent responsiveness to SF ex vivo treatment over time in human 
PBMCs. In order to evaluate the consistency of the above-analyzed markers, PBMCs were isolated from fresh 
human blood drawn for three consecutive weeks from the same healthy donor. Basal gene expression levels were 
analyzed in these PBMCs. Although there were differences in the mRNA levels for a few markers among sets of 
three consecutive blood draws from the same donor (Fig. 4), these differences were negligible when compared to 
the fold changes of these markers after stimulation (Fig. 5).
A portion of the PBMCs from the three blood draws were identically treated with vehicle (0.1% acetonitrile) 
or SF for 6 h, and cytoprotective markers of the Keap1/Nrf2/ARE pathway and the heat shock response were 
compared. In a separate experimental setting, PBMCs isolated from the above mentioned three blood draws 
were identically treated with SF for 30 min and then LPS for an additional 5 h, followed by the comparison of 
pro-inflammatory markers. Although there were differences among the three repeated blood draws for most of 
the markers (indicated by * or ** in Fig. 5), these differences were negligible when compared to the differences of 
these markers between pre- and post-treatment (indicated by ## or ### in Fig. 5).
Biomarker evaluation in PBMCs from ASD patients with in vivo SF treatment. As a pilot study 
for a clinical trial of SF in children with ASD (clinicaltrials.gov NCT02561481), we evaluated the same biomark-
ers from the ex vivo studies in 10 young males with ASD, 6-12 years of age (Table 1), who received SF (in the 
form of a dietary supplement containing GR and myrosinase), 2.2 μmol/kg/d for 14 days. We chose this dietary 
supplement, because it represents a highly standardized commercially available source of SF that could be easily 
obtained by patients and caregivers. Blood and urine samples were collected before and at the end of treatment. 
This study design allowed for each patient to serve as his own control. Notably, a placebo group was not included 
for biomarker evaluation in this pilot study, because it is difficult to subject ASD children to blood draws, and 
there are no endogenous sources of SF in human tissues, as we have shown in a previous placebo-controlled 
study67. There were no serious adverse events; one was judged by his parents to be more hyperactive, one had 
increased urinary frequency, two had increased flatus, one had nausea, and one complained of unpleasant taste. 
Figure 3. Pro-inflammatory gene expression in human PBMCs from healthy donors in response to LPS 
stimulation (a) and to SF pre-treatment plus LPS stimulation (b). Means ± SD are shown. Symbols *(p < 0.05) 
or **(p < 0.01) indicate statistical differences between treatments and controls by two-tailed Student’s t-test 
(a,b), and symbol ##(p < 0.01) indicates statistical differences between LPS stimulation and SF pre-treatment 
plus LPS stimulation (b).
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No clinical changes were reported by the families of 8 of the 10 participants. The parents of one child reported 
increased eye contact and sound sleep, another had improved behavior.
We used excretion of total isothiocyanates (ITC) and their metabolites (dithiocarbamates, DTC) in urine as a 
proxy for the bioavailability of GR delivered. Timed urine collection at the end of 14 days were used to determine 
excretion of SF and its metabolites as DTC by cyclocondensation reaction-HPLC assay. DTC levels were also 
measured in the plasma. The non-detectable or extremely low pre-dose DTC levels in both urine and plasma 
samples indicated that, as instructed, no patient was consuming a diet or supplements containing glucosinolates 
or ITC, including SF (Table 1). Conversion of GR to SF (bioavailability) was calculated as percent of dose excreted 
in collected urine samples, and was normalized on a molar equivalence basis (moles of GR to moles of SF plus 
its metabolites as determined in the cyclocondensation reaction). Conversion efficiencies varied among subjects 
from 8.2% to 68.4% of the administered dose, which is consistent with the data we and others have previously 
reported on bioavailability in adults11,68,69. Post-dose plasma DTC levels were closely related to the time between 
last dose and blood draw, with lower levels at less than 2 h or more than 14 h, and higher levels between 9-10 h 
after the last dose (Table 1). In addition, the plasma DTC value for each patient was well correlated with the 
conversion efficiency calculated in his urine sample, taking the time between last dose and blood draw into 
consideration.
Using PBMCs isolated from blood samples of six of the ten ASD subjects in the pilot study, we compared the 
expression levels of 9 molecular markers related to our hypothesized mechanisms of the action of SF. These mark-
ers were selected in large part based on their responsiveness to SF ex vivo treatment, with (a) AKR1C1, NQO1, 
HO-1 serving as markers for the Keap1/Nrf2/ARE cytoprotective pathway; (b) COX-2, TNF-α, IL-6 and IL-1β 
serving as markers for the inflammatory pathway; and (c) HSP70 and HSP27 serving as markers for the heat 
shock response.
Overall, the magnitude of change of all markers examined was smaller in the in vivo than it was in the ex vivo 
treatments. Although there was considerable variability among subjects, after 2 weeks of oral administration 
of this dietary supplement, the expression of the Nrf2-target genes NQO1, HO-1, and AKR1C1, as well as the 
heat shock response markers HSP27 and HSP70, were elevated in PBMCs from patients with ASD (Fig. 6a). 
Conversely, the levels of pro-inflammatory markers (IL-6, IL-1β, COX-2 and TNF-α) decreased (Fig. 6b). When 
differences between pre-dose (relative expression set at 1.0) and post-dose for all the tested markers were analyzed 
individually by two-tailed paired t-test, only the differences in COX-2 expression were significant (p = 0.014). 
However, grouping by broad functionality (e.g. cytoprotective or pro-inflammatory), differences from baseline 
were highly significant at the 95% confidence level by ANOVA (F1,52 = 8.82, p < 0.005 for cytoprotective genes and 
F1,46 = 9.25, p < 0.004 for pro-inflammatory genes) (Fig. 6c).
Discussion
Development of reliable ASD biomarkers is critical for elucidating ASD pathobiology, improving diagnosis and 
monitoring therapeutic effects. The brain is the central affected organ in ASD, despite significant comorbidities in 
other systems, notably the gastrointestinal tract. Studies examining neural tissue are, therefore, likely to be more 
informative than analyses of other tissues in terms of understanding the pathogenesis of brain dysfunction in 
ASD. However, brain biopsy- or cerebrospinal fluid-based biomarkers are invasive, MRI and PET-based imaging 
biomarkers are expensive and difficult to perform, which limits their appeal to both patients and physicians. There 
is now growing interest in identification of molecular biomarkers that are less- or non-invasive, cost-effective, and 
readily available in clinical settings. Therefore, reliable blood-based biomarkers are considered essential for ASD.
We used human PBMCs isolated from blood of healthy donors and patients with ASD to explore poten-
tial biomarkers in response to SF in ASD. Expression of markers of three signaling pathways related to ASD 
pathophysiology were evaluated by quantitative real-time PCR. Three representative Nrf2-dependent enzymes, 
AKR1C1, NQO1 and HO-1, were significantly induced by 6 h of 2 μM or 5 μM SF ex vivo treatments in PBMCs 
from healthy donors. However, AKR1B10 was not induced. In the hands of other investigators, the AKR1 sub-
family of aldo-keto reductases was the most highly upregulated family of genes through the Keap1/Nrf2 pathway 
Figure 4. Basal gene expression levels in human PBMCs isolated from three blood samples of the same healthy 
donor. Means ± SD are shown. Symbols *(p < 0.05) or **(p < 0.01) indicate statistical differences among three 
blood draws by one-way ANOVA.
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in human gut mucosa and different cell lines70–72; these genes were thus thought to be good biomarker candidates. 
We chose AKR1C1 and AKR1B10 as Nrf2-dependent markers in our study since they were highly responsive 
to SF treatment in human breast epithelial cells and keratinocytes71,72. Notably however, although AKR1C1 and 
AKR1B10 share Nrf2 as a transcriptional regulator, AKR1B10 is also regulated by p5373. AKR1C1 and NQO1, 
but not HO-1, were also induced by a lower dose of SF (0.5 μM) over a 3-day treatment. Although the heat shock 
response marker HSP70 was not very responsive to the SF concentrations we used for the ex vivo treatment, the 
change was statistically significant following treatment for 6 h with 2 or 5 μM SF. We also evaluated expression of 
the transcription factors of the above two pathways, Nrf2 and HSF1, in response to SF treatment in PBMCs from 
healthy donors. Nrf2 is primarily regulated at the level of its protein stability, whereas HSF1 is mainly regulated 
by post-translational modifications. As expected, their expression levels were not responsive to SF ex vivo treat-
ment. However, comparing their basal expression levels in PBMCs from ASD patients to age-matched healthy 
controls may provide valuable information on pathological mechanisms of ASD. An earlier clinical study showed 
that Nrf2 mRNA levels are substantially depressed in granulocytes of ASD children (45% of the levels in typically 
Figure 5. Consistency of gene expression in human PBMCs from healthy donors in response to ex vivo 
treatment among three blood samples of the same healthy donor. Means ± SD are shown. Symbols *(p < 0.05) 
or **(p < 0.01) indicate statistical differences among three blood draws by one-way ANOVA, and symbols 
##(p < 0.01) or ###(p < 0.001) indicate statistical differences between treatments by two-tailed Student’s t-test.
Subjects*
Age
Pre-Dose 
DTC % Excretion
Plasma DTC (nmol/
mL)
Time between 
last dose
(Years) in urine in urine pre-dose post-dose and blood draw
1 9 none 54.1 0.004 0.052 15.9
2 10 none 16.1 0.006 0.159 8.9
3 6 none 10.3 0.002 0.088 7.5
4 12 none 52.4 0.026 0.257 9.7
5 9 none 68.4 0.007 0.307 9.4
6 10 none 8.2 0.008 0.014 19.1
7 10 none 30.4 0.011 0.13 7.25
8 12 none 37.2 0.019 0.016 1.9
9 9 none 37.6 0.047 0.09 1.75
10 9 none 29.4 0.003 0.16 14
Table 1. Sulforaphane bioavailability as a function of treatment. *All subjects are males.
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developing children)74. Keap1, as the cytoplasmic regulator of Nrf2 activity, had slightly increased expression 
following SF treatment, however, SF induces the Nrf2-dependent enzymes mainly through modifying specific 
and highly reactive cysteine residues of Keap1 and not by changing its expression13,75. Moreover, SF ex vivo 
pre-treatment significantly decreased the LPS-stimulated inflammatory gene (COX-2, TNF-α, IL-6 and IL-1β) 
expression levels in PBMCs from healthy donors.
Although variable basal gene expression levels are manifest in PBMCs of different blood donors, the trends of 
their responsiveness to treatment were similar. More importantly, basal gene expression of our tested markers in 
PBMCs from different blood draws from the same donor were very similar, and the differences in responsiveness 
to treatment among the PBMCs from different blood draws were negligible when compared to the fold changes 
of these markers in response to treatments. Therefore, these markers have the potential to serve as biomarker 
candidates.
This study represents our attempt to develop biomarkers and explore molecular basis of the treatment effects 
of SF on patients with ASD. The in vivo evaluation of selected markers is a pilot study for a clinical trial of SF in 
children with ASD (clinicaltrials.gov NCT02561481). By executing this pilot study, we expected to gather informa-
tion on the reproducibility of individual biomarker values and magnitudes of changes resulting from short term 
SF intervention and to identify the precise biomarker endpoints that would be measured in the main clinical trial. 
Although we collected urine and blood samples from 10 subjects, unfortunately, the RNA quality from PBMCs 
of the first 3 participants was compromised due to inappropriate processing and storage, and 1 participant had a 
gastrointestinal infection at the time of the post-treatment blood draw, which limited our in vivo biomarker eval-
uation to samples from 6 participants. Perhaps due to the relatively small sample size, the increased expression of 
individual cytoprotective markers (NQO1, AKR1C1, HO-1, HSP70 and HSP27) and the decreased expression of 
most individual pro-inflammatory markers (IL-6, IL-1β and TNF-α), except that of COX-2, after 2 weeks of SF 
treatment did not reach statistical significance. However, the functionally grouped markers showed great poten-
tial as panel biomarkers to guide treatment strategies and enable clinicians to monitor treatment responses. In 
addition, our pilot study only exposed participants to SF for 2 weeks, which is less than the exposure that resulted 
in changes in clinical symptoms in our previous study18. Longer exposure times may well be necessary, and the 
Figure 6. Gene expression level changes in PBMCs from 6 patients with ASD after SF intervention. SF was 
orally administered daily at the dose of 2.2 μmol/kg body weight in the form of GR plus myrosinase for two 
weeks. Expression level of each gene immediately prior to treatment was set as control. (a) Cytoprotective 
genes. (b) Pro-inflammatory genes. (c) Grouped genes by broad functionality (e.g. cytoprotective or pro-
inflammatory). Differences between pre-dose and post-dose for individual markers were analyzed by two-
tailed paired t-test, and p-values for each marker are the numbers in parentheses above the top error bars (a,b). 
Differences of grouped markers from baseline were analyzed by one-way ANOVA, and symbol ** indicates 
highly significant statistical difference (p < 0.01) (c). Data points for each subject (a,b) or means of each group 
of genes (c) are plotted. Horizontal lines within boxes are means.
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correlation between biomarker changes and clinical improvements will be reported from the recently completed 
full clinical trial.
In conclusion, in the above ex vivo and in vivo experiments using human PBMCs from healthy donors and 
patients with ASD, the tested markers show potential as biomarkers for monitoring SF responses in humans. 
They are quantifiable, and the assay method is accurate and reproducible; the samples are readily obtainable in 
quantities needed for measurement, and sampling is minimally invasive. Most importantly, the biomarkers show 
sensitivity and consistent responsiveness to SF treatment both ex vivo and in vivo. Although as a single marker, 
none of them is specific or sensitive enough, these biomarkers, grouped by function as two panels, show promise 
in monitoring responses to treatments, and in providing guidance for the selection and efficacy of biomedical 
interventions. We conducted this study in the context of ASD, however our findings have broader implications 
and suggest that these biomarkers can be used in any study involving an intervention with SF.
Methods
Participants and treatment. For the ex vivo experiments, 7 healthy adult donors were recruited. Blood 
was drawn a single time from 5 donors. Two of them each had blood drawn weekly, for 3 consecutive weeks. All 
experiments were performed in accordance with relevant guidelines and regulations at Johns Hopkins University 
and informed consent was obtained from all participants prior to blood collection, under a research protocol 
approved by the Institutional Review Board of Johns Hopkins University School of Medicine (NA_00036496).
As a pilot study for a clinical trial of SF in children with ASD (clinicaltrials.gov NCT02561481), 10 young 
males with ASD, 6-12.5 years of age (mean, 9.9 years) were recruited to evaluate potential blood-based bio-
markers in response to oral SF treatment. This study was conducted at the UMass Memorial Medical Center and 
University of Massachusetts Medical School, and Johns Hopkins University with approval from the Institutional 
Review Boards of both institutions (IRBH00007832 and IRB00084331). The diagnosis of moderate to severe 
ASD was confirmed by testing using the Autism Diagnostic Observation Schedule (ADOS)76 and all subjects had 
screening medical histories, examinations and normal clinical laboratory screening following parental consent. 
Each subject received SF in the form of Avmacol tablets (crushable), each containing 12.5-15 mg glucoraphanin 
(GR, the precursor of SF) and active plant-derived myrosinase (the enzyme that converts GR to SF). Tablets were 
provided along with a COA, by Nutramax Laboratories, Inc. (Edgewater, Maryland, USA), under an IND from 
the US FDA. Dosing was calibrated to ca. 2.2 μmol SF/kg body weight per day for 14 days. Subjects’ blood and 
urine samples were collected before, and at the end of the treatment period. All experiments were performed in 
accordance with relevant guidelines and regulations at University of Massachusetts and Johns Hopkins University.
Primers Sequences
Keap1
forward 5′-GGG TCC CCT ACA GCC AAG-3′
reverse 5′-TGG GGT TCC AGA AGA TAA GC-3′
Nrf2
forward 5′-ACA CGG TCC ACA GCT CAT C-3′
reverse 5′-TGC CTC CAA AGT ATG TCA ATC A-3′
NQO1
forward 5′-CAG CTC ACC GAG AGC CTA GT-3′
reverse 5′-GAG TGA GCC AGT ACG ATC AGT G-3′
AKR1C1
forward 5′-CGC CTG CAG AGG TTC CTA AAA-3′
reverse 5′-ATC AAT ATG GCG GAA GCC AG-3′
HO-1
forward 5′-GGG TGA TAG AAG AGG CCA AGA-3′
reverse 5′-AGC TCC TGC AAC TCC TCA AA-3′
HSF1
forward 5′-CAT GAA GCA TGA GAA TGA GGC T-3′
reverse 5′-ACT GCA CAG TGA GAT CAG GA-3′
HSP70
forward 5′-ATG AGT ATA GCG ACC GCT GC-3′
reverse 5′-TCC TTG GAC TGT GTT CTT TGC-3′
HSP27
forward 5′-TCC CTG GAT GTC AAC CAC TTC-3′
reverse 5′-TCT CCA CCA CGC CAT CCT-3′
COX-2
forward 5′-CAG CAC TTC ACG CAT CAG TTT T-3′
reverse 5′-CCA GCC CGT TGG TGA AAG-3′
iNOS
forward 5′-TGG ATG CAA CCC CAT TGT C-3′
reverse 5′-CGC TGC CCC AGT TTT TGA T-3′
TNF-α
forward 5′-ATC TTC TCG AAC CCC GAG TGA-3′
reverse 5′-CGG TTC AGC CAC TGG AGC T-3′
IL-6
forward 5′-CGA GCC CAC CGG GAA CGA AA-3′
reverse 5′-GGA CCG AAG GCG CTT GTG GAG-3′
IL-1β
forward 5′-CAC GCT CCG GGA CTC ACA GC-3′
reverse 5′-GGA GAA CAC CAC TTG TTG CTC CA-3′
GAPDH
forward 5′-TGG TAT CGT GGA AGG ACT CA-3′
reverse 5′-GGG CCA TCG ACA GTC TTC-3′
Table 2. Sequences of real-time PCR primers.
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Blood sample collection and PBMC isolation. Eight mL of whole blood were drawn from the partici-
pants into Vacutainer CPT tubes (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) at room temper-
ature and processed for PBMC isolation according to the instructions from the manufacturer. Briefly, blood in a 
CPT tube was centrifuged, PBMCs suspended in a small amount of plasma were transferred to a 50-mL conical 
tube, and PBMCs were washed twice with phosphate buffered saline. Isolated PBMC pellets from healthy donors 
were re-suspended in warm RPMI 1640 culture medium with 10% heat-inactivated FBS for ex vivo treatment. 
PBMC pellets isolated from ASD patients were stored at −80 °C for future RNA isolation.
Ex vivo treatment of PBMCs. PBMCs isolated from blood of a healthy donor were plated in 6-well plates 
(~4 × 106 cells/well) in RPMI 1640 medium plus 10% heat-inactivated FBS. After incubation for 2 h, some of 
the cells were treated with vehicle (0.1% acetonitrile) or SF (2 μM and 5 μM) for 6 h, or exposed to vehicle (0.1% 
acetonitrile) or low dose SF (0.5 μM) repeatedly for 3 consecutive days. Meanwhile, some of the PBMCs were 
exposed to vehicle or SF for 30 min and then lipopolysacharide (LPS) for an additional 5 h to stimulate inflamma-
tory response. After treatments, cells were collected for RNA isolation.
Total RNA isolation and quantitative real-time PCR. Total cellular RNA was isolated from PBMCs 
using the RNeasy mini kit (Qiagen, Valencia, CA, USA). RNA quantity and quality were measured with the 
NanoDrop2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) and complementary DNAs 
(1 µg) were synthesized using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA, USA). 
Quantitative real-time PCR analysis was performed using the Applied Biosystems QuantStudio 3 Real-Time PCR 
System (Thermo Fisher Scientific, Waltham, MA, USA). All primers were optimized, and a final primer concen-
tration of 300 nM was used for all reactions. Primer sequences for gene amplification are shown in Table 2. The 
reactions were assembled using 2.5~25 ng of cDNA, 1× PowerUp SYBR Green Master Mix (Applied Biosystems, 
Thermo Fisher Scientific, Waltham, MA, USA), forward and reverse primers, and nuclease-free water. Relative 
mRNA expression was normalized to GAPDH. Gene expression was calculated using the comparative 2−ΔΔCT 
method77,78.
Statistical analysis. All conclusions drawn for ex vivo studies were derived from at least three independent 
experiments. Results shown in Figs. 2–5 were means ± SD of three replicates for every real-time PCR reaction 
within a representative experiment. Differences between treatments and controls were evaluated by two-tailed 
Student’s t-test with p < 0.05 or p < 0.01 being considered statistically significant or highly significant, respec-
tively. Differences among three or more groups were analyzed by one-way analysis of variance (ANOVA). For in 
vivo studies with ASD patients, the differences between pre-dose and post-dose expression levels of each tested 
marker were evaluated by two-tailed paired t-tests. Grouped markers were analyzed by one-way ANOVA.
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author upon reasonable requests.
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